statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis...

Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...

Pliant Therapeutics to Participate in Upcoming Investor Events

This indicator may be signaling that PLRX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Pliant Therapeutics (PLRX, $14.81) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

For the last three days, A.I.dvisor has detected that PLRX's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Pliant Therapeutics (PLRX, $14.81) Aroon Indicator entered a Downtrend on April 01, 2024.

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten analysts that are currently covering the firm, Marketbeat.com...

Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Price Target at $48.44

Pliant Therapeutics (PLRX, $14.88) Aroon Indicator entered a Downtrend on March 28, 2024.

This is a Bullish indicator signaling PLRX's price could rise from here. Traders may explore going long the stock or buying call options...

Pliant Therapeutics (PLRX, $14.88) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

Pliant Therapeutics (PLRX, $14.54) Aroon Indicator entered a Downtrend on March 27, 2024.

Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq...

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast's time to Phase 3 data Upsized Oxford Finance debt...

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Watchers	1,183
52-Wk Low	$11.21
52-Wk High	$24.74

Volume	372,754.00
52-Wk High	$24.74
52-Wk Low	$11.21

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.85	--	--	N/A
Q1'24	-$0.77	-$0.78	-1.06%	MISSED
Q4'23	-$0.81	-$0.69	15.18%	BEAT
Q3'23	-$0.78	-$0.70	9.71%	BEAT
Q2'23	-$0.71	-$0.70	1.86%	BEAT

PLRX Pliant Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals